Day One

• Identifying how and why B cells drive autoimmune pathology 
• Understanding the mechanistic basis for efficacy of B-cell depletion in treating autoimmune diseases 
• Understanding modalities of B cell depletion and their limitations, with an eye toward the design of next generation and more precise approaches

• Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
• Harnessing base editing to enable CAR T-cell combination therapies for B-cell targeting and beyond
• Discussing the possibility of B-cell reconstitution, focusing on whether the new B-cell compartment is “reset” to a non-autoreactive state

Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

• Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
• Addressing the risks associated at various level of depletion such as elevated BAFF
• Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the immune resetting field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.

• Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
• Harnessing available clinical data to inform target selection and match T-cell engager targets to the correct autoimmune indication
• Exploring the dosing challenges for high-efficacy T-cell engagers and determining whether intermittent high doses or continuous lower doses are optimal to balance efficacy and safety

• Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
• Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
• Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs

• Novel T-cell engager for autoimmune diseases
• CD19 and BCMA targeting therapies for B-cell and plasma cell depletion
• New therapeutic approaches for drug for immune resetting

• Leveraging extensive CAR T cell manufacturing experience to establish the nextgeneration NEX-T manufacturing process
• Assessing the pharmacokinetics and pharmacodynamics of NEX-T CAR T cell therapy in a diverse patient population
• Establishing pooled safety and preliminary efficacy of NEX-T CAR T cell therapy in severe refractory autoimmune diseases

• Securing Centre’s of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
• Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
• Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible

• Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
• Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
• Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population